中文摘要：

去势抵抗性前列腺癌（CRPC）患者预后极差。CRPC的发生和进展机制极为复杂,迄今尚未被完全阐明,因此治疗策略的选择仍是临床上极具挑战性的问题。近年来,治疗CRPC的新药不断涌现,包括雄激素合成抑制药物（阿比特龙）、雄激素受体（AR）抑制药物（恩杂鲁胺）、免疫治疗剂（sipuleucel-T）、放射剂（镭-223）和化疗药物（卡巴他赛）等。因而,针对CRPC的治疗有了更多选择,系统治疗亦发生了很大变化。简要综述近年来人们对CRPC发生发展机制的最新理解和最有前途的药物在CRPC治疗中获得的新进展。

英文摘要：

Castration-resistant prostate cancer （CRPC） has an extremely poor prognosis and remains a significant clinical challenge as the underlying mechanisms are largely unknown. Recently, a broad range of novel therapeutic drugs has emerged for CRPC treatment, including androgen synthesis inhibitors （abiraterone）, androgen receptor （AR） inhibitors （ enzalutamide）, immunotherapy （ sipuleucel-T ）, radiopharmaceuticals （ Radium-223 ） and chemotherapeutic agents （cabazitaxel）. Therefore, clinical urologists have more choices for the treatment of CRPC patients and the strategies of the systematic therapy have undergone great changes. In this review, we briefly overviewed the current molecular understanding of CRPC and highlighted the recently approved and emerging therapeutics for patients with CRPC.